Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,240,640 papers from all fields of science
Search
Sign In
Create Free Account
DX 8951
Known as:
DX-8951
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
exatecan
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
T. Iwata
,
Chiaki Ishii
,
S. Ishida
,
Y. Ogitani
,
T. Wada
,
T. Agatsuma
Molecular Cancer Therapeutics
2018
Corpus ID: 20160210
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with a topoisomerase I inhibitor exatecan derivative…
Expand
2007
2007
Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors.
Y. Shiose
,
Y. Ochi
,
H. Kuga
,
F. Yamashita
,
M. Hashida
Biological & pharmaceutical bulletin
2007
Corpus ID: 46102059
DE-310 is composed of the topoisomerase-I inhibitor DX-8951 (exatecan) and carboxymethyldextran polyalcohol (CM-Dex-PA) carrier…
Expand
2005
2005
DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors
M. Wente
,
J. Kleeff
,
+4 authors
H. Friess
Investigational New Drugs
2005
Corpus ID: 1760800
Background: DE-310 is composed of the topoisomerase-I-inhibitor DX-8951 (exatecan) and a biodegradable macromolecular carrier…
Expand
2005
2005
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer
J. Ajani
,
C. Takimoto
,
+7 authors
R. Jager
Investigational New Drugs
2005
Corpus ID: 7414878
Purpose: To determine the anti-tumor activity DX-8951f when administered as a 30-minute infusion daily for 5 days every 3 weeks…
Expand
Highly Cited
2005
Highly Cited
2005
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
O. Soepenberg
,
M. D. de Jonge
,
+7 authors
J. Verweij
Clinical cancer research : an official journal of…
2005
Corpus ID: 14404513
PURPOSE To assess the maximum-tolerated dose, toxicity, and pharmacokinetics of DE-310, a macromolecular prodrug of the…
Expand
2004
2004
A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951
Y. Ochi
,
Y. Shiose
,
H. Kuga
,
E. Kumazawa
Cancer Chemotherapy and Pharmacology
2004
Corpus ID: 42366266
DE-310, a new macromolecular prodrug, was designed to enhance the pharmacological profiles of a novel camptothecin analog (DX…
Expand
2002
2002
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
F. Giles
,
J. Cortes
,
+5 authors
H. Kantarjian
Clinical cancer research : an official journal of…
2002
Corpus ID: 7507154
PURPOSE DX-8951f is a novel hexacyclic camptothecin-analogue topoisomerase I inhibitor with both in vitro antileukemic activity…
Expand
2000
2000
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
E. Rowinsky
,
T. Johnson
,
+10 authors
R. D. De Jager
Journal of clinical oncology : official journal…
2000
Corpus ID: 30525792
PURPOSE To assess the feasibility of administering DX-8951f (exatecan mesylate), a water-soluble, camptothecin analog, as a 30…
Expand
Review
2000
Review
2000
DX‐8951f: Summary of Phase I Clinical Trials
R. Jager
,
P. Cheverton
,
+5 authors
M. Suzuki
Annals of the New York Academy of Sciences
2000
Corpus ID: 40816714
Abstract: Exatecan mesylate (DX‐8951f) is a new hexacyclic camptothecin analogue with favorable attributes compared to topotecan…
Expand
1997
1997
Antitumor Effect of DX‐8951, a Novel Camptothecin Analog, on Human Pancreatic Tumor Cells and Their CPT‐11‐resistant Variants Cultured in vitro and Xenografted into Nude Mice
S. Takiguchi
,
E. Kumazawa
,
T. Shimazoe
,
A. Tohgo
,
A. Kono
Japanese journal of cancer research : Gann
1997
Corpus ID: 13718482
DX‐8951 is a novel water‐soluble derivative of camptothecin. We evaluated the effects of DX‐8951 on the growth of several…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE